retatrutide triple agonist glp-1 gip glucagon phase 3 2025 is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. π¬ Latest data highlights: β’ ~25β30% average body-weight reduction in long-term trials Retatrutide Guide: Dosing, Results, Calculator
Pay in 4 interest-free payments of $6.87 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Jul 31 - Aug 5
























